1. Home
  2. CAPR vs FOR Comparison

CAPR vs FOR Comparison

Compare CAPR & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$30.60

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Forestar Group Inc

FOR

Forestar Group Inc

N/A

Current Price

$25.46

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
FOR
Founded
2005
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2011
2007

Fundamental Metrics

Financial Performance
Metric
CAPR
FOR
Price
$30.60
$25.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$41.38
$31.75
AVG Volume (30 Days)
921.3K
117.8K
Earning Date
01-01-0001
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
$22,270,465.00
$1,662,400,000.00
Revenue This Year
N/A
$0.52
Revenue Next Year
$17,308.50
$7.72
P/E Ratio
N/A
$86.45
Revenue Growth
N/A
10.14
52 Week Low
$4.30
$18.00
52 Week High
$40.37
$30.74

Technical Indicators

Market Signals
Indicator
CAPR
FOR
Relative Strength Index (RSI) 66.95 32.41
Support Level $22.09 $24.05
Resistance Level $40.37 $26.00
Average True Range (ATR) 1.84 0.92
MACD 0.17 -0.53
Stochastic Oscillator 92.68 16.74

Price Performance

Historical Comparison
CAPR
FOR

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

Share on Social Networks: